Production (Stage)
Evelo Biosciences, Inc.
EVLO
$0.0005
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.51% | -34.69% | -21.78% | -5.80% | 15.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.76% | -22.00% | -10.32% | -6.01% | -0.95% |
| Operating Income | 35.76% | 22.00% | 10.32% | 6.01% | 0.95% |
| Income Before Tax | 31.65% | 18.61% | 11.64% | 6.69% | 2.38% |
| Income Tax Expenses | 87.37% | 93.42% | 127.25% | 117.29% | -6.94% |
| Earnings from Continuing Operations | 31.17% | 18.12% | 11.17% | 6.26% | 2.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.17% | 18.12% | 11.17% | 6.26% | 2.40% |
| EBIT | 35.76% | 22.00% | 10.32% | 6.01% | 0.95% |
| EBITDA | 35.96% | 22.16% | 10.33% | 5.99% | 0.84% |
| EPS Basic | 62.47% | 56.99% | 51.23% | 36.84% | 25.71% |
| Normalized Basic EPS | 64.26% | 58.37% | 50.38% | 35.57% | 23.75% |
| EPS Diluted | 62.47% | 56.99% | 51.23% | 36.84% | 25.71% |
| Normalized Diluted EPS | 64.26% | 58.37% | 50.38% | 35.57% | 23.75% |
| Average Basic Shares Outstanding | 133.75% | 86.37% | 89.07% | 64.04% | 42.00% |
| Average Diluted Shares Outstanding | 133.75% | 86.37% | 89.07% | 64.04% | 42.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |